BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34302727)

  • 21. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
    Nucera C; Porrello A; Antonello ZA; Mekel M; Nehs MA; Giordano TJ; Gerald D; Benjamin LE; Priolo C; Puxeddu E; Finn S; Jarzab B; Hodin RA; Pontecorvi A; Nose V; Lawler J; Parangi S
    Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10649-54. PubMed ID: 20498063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance in DNA repair machinery is associated with BRAF
    Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
    Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
    Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
    Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
    Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
    Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
    Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
    BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an
    Ito Y; Ishikawa H; Kihara M; Hirokawa M; Kiyota N; Kasahara T; Miyauchi A
    Thyroid; 2019 Oct; 29(10):1511-1517. PubMed ID: 31317827
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
    Yarchoan M; Ma C; Troxel AB; Stopenski SJ; Tang W; Cohen AB; Pappas-Paxinos M; Johnson BA; Chen EY; Feldman MD; Brose MS
    Horm Cancer; 2016 Jun; 7(3):188-95. PubMed ID: 26994002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.
    Yun HJ; Kim M; Kim SY; Fang S; Kim Y; Chang HS; Chang HJ; Park KC
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.
    Yin L; He J; Xue J; Na F; Tong R; Wang J; Gao H; Tang F; Mo X; Deng L; Lu Y
    Biomed Pharmacother; 2018 Mar; 99():615-621. PubMed ID: 29653486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
    Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
    Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
    Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.